Deals
Sanofi's Viehbacher Secures Genzyme Growth With Hard Line Offer
This article is for subscribers only.
When Chris Viehbacher, the chief executive of Paris-based drugmaker Sanofi-Aventis SA, was trying to keep details of his unsolicited bid last year for Genzyme Corp. under wraps, he couldn’t resist drawing on his beloved Bordeaux.
“I really like French wines,” the 50-year-old German-Canadian said yesterday after sealing his sometimes rancorous nine-month pursuit of Cambridge, Massachusetts-based Genzyme, an acquisition valued at $20.1 billion.